Fig. 8: Homoharringtonine and Halofuginone show efficacy in blunting SARS CoV-2 infection. | Nature Communications

Fig. 8: Homoharringtonine and Halofuginone show efficacy in blunting SARS CoV-2 infection.

From: A high-throughput screen for TMPRSS2 expression identifies FDA-approved compounds that can limit SARS-CoV-2 entry

Fig. 8: Homoharringtonine and Halofuginone show efficacy in blunting SARS CoV-2 infection.The alternative text for this image may have been generated using AI.

A Schematic of SARS-CoV-2 treatment strategy. Calu-3 cells were pretreated with Halofuginone (HFG) or Homoharringtonine (HHT) for 24 h. Media was exchanged, and cells were exposed to SARS-CoV-2 virus for 75 min, then exchanged for fresh media replenished with HFG or HHT. Supernatant samples were taken at 48 and 72 h for qPCR analysis of viral RNA (B–I). B–I qPCR analysis of viral RNA in culture supernatant of Calu-3 cells under titration of HFG or HHT at 48 h following an initial infection of SARS-CoV-2 using an MOI of 0.01 (B–C), or 0.001 (D–E), or at 72 h after infection with an initial MOI of 0.01 (F–G) or 0.001 (H–I). Data represent mean ± SEM (n = 3 biologically independent samples).

Back to article page